Table 3.

Type and prevalence of antipsychotic agents among US adults ages 18 and older with major depressive disorder (MDD) who were antipsychotics prescribed, 2006–2015 NAMCS.

	Years (%)					Overall (%)	P-value†
	2006–2007	2008–2009	2010–2011	2012–2013	2014–2015
Any typical (first generation) agents	5.7	8.0	5.0	2.2	3.1	4.9	0.253
Typical (first generation) - Butyrophenones
Haloperidol	1.7	3.8	0.4	0.0	1.5	1.6	0.124
Typical (first generation) - Phenothiazines
Chlorpromazine	1.8	0.9	0.0	0.0	0.0	0.5	0.587
Fluphenazine	0.6	0.0	0.0	0.0	0.9	0.3	0.776
Perphenazine	1.1	0.0	2.7	0.3	0.7	1.0	0.132
Prochlorperazine	0.0	1.1	0.0	0.0	0.0	0.2	0.761
Thioridazine hydrochloride	0.0	0.2	0.0	0.9	0.0	0.2	0.724
Trifluoperazine hydrochloride	0.5	0.4	0.0	1.0	0.0	0.3	0.708
Typical (first generation) - Thiothixene
Thiothixene	0.0	1.2	1.9	0.9	0.0	0.9	0.611
Typical (first generation) - Miscellaneous
Loxapine succinate	0.0	0.0	0.0	0.0	0.0	0.0	-
Molindone hydrochloride	0.0	0.0	0.0	0.0	0.0	0.0	-
Pimozide	0.0	0.5	0.0	0.0	0.0	0.1	0.896
Any atypical (second generation) agents	96.1	95.6	96.1	98.1	98.3	96.8	0.562
Atypical (second generation)
Aripiprazole‡	15.9	30.9	26.1	30.5	32.9	27.7	0.147
Asenapine	0.0	0.0	0.0	2.4	0.3	0.5	0.321
Clozapine	0.0	1.0	0.0	0.2	0.0	0.3	0.733
Iloperidone	0.0	0.0	0.0	0.0	0.0	0.0	-
Lurasidone	0.0	0.0	0.3	2.6	2.9	1.2	0.168
Olanzapine‡	15.8	6.0	8.3	6.5	8.5	8.7	0.130
Paliperidone	0.0	0.0	2.2	2.7	0.3	1.0	0.340
Quetiapine‡	42.1	37.1	35.0	28.0	37.6	36.0	0.459
Risperidone‡	24.6	20.9	20.8	23.4	21.2	22.0	0.971
Ziprasidone‡	3.7	7.0	6.5	5.4	2.3	5.1	0.491

Note:

^†compares proportion differences across years using a weight-corrected Pearson’s chi-squared statistic.

^‡indicates approved and off-label uses by the FDA for MMD.